HedgeCo.Net — AI-native drug discovery company Enveda closed a $311 million Series E on September 23, 2026 at a $2 billion valuation led by Catalio Capital Management, according to TechCrunch and the company’s BioSpace press release. Coverage said the round roughly doubled the company’s valuation from about a year earlier.
New and existing investors named in the company materials include Durable, ICONIQ, Lightspeed, Surveyor Capital (a Citadel company), T. Rowe Price accounts, Baillie Gifford, Lux Capital and others. Per the company PR, total capital raised since inception now exceeds $845 million.
For allocators watching AI-biotech mega-rounds, the hard marks are the $311 million Series E, $2 billion valuation, Catalio lead, named co-investor roster, and >$845 million cumulative capital. Do not invent pipeline milestones, clinical-trial counts, or undisclosed ownership splits beyond what the sources published.